Calvin Kuo - Surrozen Warrant CoFounder Advisor
| SRZNW Stock | USD 0.02 0.01 21.74% |
Insider
Calvin Kuo is CoFounder Advisor of Surrozen Warrant
| Address | 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 489 9000 |
| Web | https://www.surrozen.com |
Surrozen Warrant Management Efficiency
The company has return on total asset (ROA) of (0.3265) % which means that it has lost $0.3265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7359) %, meaning that it generated substantial loss on money invested by shareholders. Surrozen Warrant's management efficiency ratios could be used to measure how well Surrozen Warrant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2024. Return On Capital Employed is likely to drop to -1.23 in 2024. At this time, Surrozen Warrant's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 3.4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 740.1 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Anna MBA | Mersana Therapeutics | 60 | |
| Adam Levy | Zentalis Pharmaceuticals Llc | N/A | |
| Carrie MD | Zentalis Pharmaceuticals Llc | 54 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Michael MBA | Syndax Pharmaceuticals | 53 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Kevin Bunker | Zentalis Pharmaceuticals Llc | 52 | |
| Friedrich MD | Iovance Biotherapeutics | 57 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Carla Poulson | Mersana Therapeutics | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Mark Lackner | Zentalis Pharmaceuticals Llc | 56 | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| JeanMarc MBA | Iovance Biotherapeutics | 52 | |
| Meena Rao | Zentalis Pharmaceuticals Llc | N/A | |
Management Performance
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.33 |
Surrozen Warrant Leadership Team
Elected by the shareholders, the Surrozen Warrant's board of directors comprises two types of representatives: Surrozen Warrant inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surrozen. The board's role is to monitor Surrozen Warrant's management team and ensure that shareholders' interests are well served. Surrozen Warrant's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surrozen Warrant's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Williams, Chief Officer | ||
| Roeland Nusse, CoFounder Advisor | ||
| Sheela MohanPeterson, VP Legal | ||
| Esther Jhun, Controller | ||
| Reza MBA, VP Strategy | ||
| MBA MD, Chief Officer | ||
| Craig MBA, President CEO | ||
| Johannes MD, CoFounder Advisor | ||
| Li Yang, Executive Research | ||
| WenChen MD, Chief Officer | ||
| Calvin MD, CoFounder Advisor | ||
| Christopher Garcia, CoFounder Advisor | ||
| Calvin Kuo, CoFounder Advisor |
Surrozen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Surrozen Warrant a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | 0.12 % | ||||
| Number Of Shares Shorted | 55.19 K | ||||
| Revenue | 12.5 M | ||||
| EBITDA | (41.13 M) | ||||
| Net Income | (43.04 M) | ||||
| Cash And Equivalents | 25.45 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 3.38 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Surrozen Stock Analysis
When running Surrozen Warrant's price analysis, check to measure Surrozen Warrant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surrozen Warrant is operating at the current time. Most of Surrozen Warrant's value examination focuses on studying past and present price action to predict the probability of Surrozen Warrant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surrozen Warrant's price. Additionally, you may evaluate how the addition of Surrozen Warrant to your portfolios can decrease your overall portfolio volatility.